# PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

> **NCT01037556** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Proacta, Incorporated** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** PR104

## Key facts

- **NCT ID:** NCT01037556
- **Lead sponsor:** Proacta, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2012-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01037556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01037556, "PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01037556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*